IST confident on licensing deal as multiple myeloma antibody moves forward
This article was originally published in Scrip
Immune System Therapeutics (IST) expects to conclude a partnering deal for its lead development project by the end of the year, a move that would boost the Australian biotech's prospects for the Phase III development and commercialisation of the multiple myeloma (MM) therapy.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.